AIM
PTGX icon

Aigen Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Aigen Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,527
Closed -$208K – 1033
2023
Q2 		$208K Buy
+7,527
New +$188K 0.03% 606
2020
Q3 		– Sell
-12,689
Closed -$224K – 1067
2020
Q2 		$224K Buy
+12,689
New +$159K 0.03% 678

Other funds holding PTGX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aigen Investment Management's PTGX Position: Q3 2023 in Review

Aigen Investment Management sold out of Protagonist Therapeutics (PTGX) in Q3 2023, closing a stake of 7,527 shares — an estimated $208K sold.

Aigen Investment Management first reported a position in PTGX in Q2 2020 and held it in 2 quarters. The position peaked at $224K in Q2 2020. 144 funds tracked by Wall St. Rank hold PTGX as of Q3 2023.

  • Aigen Investment Management reported no remaining Protagonist Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Aigen Investment Management sold 7,527 Protagonist Therapeutics shares in Q3 2023, an estimated $208K.
  • Aigen Investment Management first reported a position in Protagonist Therapeutics in Q2 2020 and held it in 2 quarters.
  • Aigen Investment Management's Protagonist Therapeutics position peaked at $224K in Q2 2020.
  • 144 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2023.

Based on Aigen Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.